Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Autism

    Boston, MA

    Search
    Autism
    Boston, MA
    Show Map
    Map View
    Boston, MA
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      125 Autism Trials near Boston, MA

      Power is an online platform that helps thousands of Autism patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      DHA for Autism

      Piscataway, New Jersey
      Dr. Sherie Novotny of the Department of Psychiatry at UMDNJ-RWJMS and collaborators are starting a treatment trial to determine whether Docosa Hexanoic Acid(DHA), the major omega-3 fatty acid found in the brain and a component of fish oil, has any effects on the symptoms of autism. We propose to carry out a trial to test the effect of DHA compared to a placebo (a pill with no drug in it) on several aspects of autism in children and adolescents, in a 12-week clinical study with children or adolescents in the age group of 5-17 with a diagnosis of Autism Spectrum Disorder. Additionally this trial will study genes related to the therapeutic agent, DHA, and biomarkers related to DHA in the urine.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:5 - 17

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Schizophrenia, Epilepsy, Others
      Must Be Taking:Anticonvulsants

      132 Participants Needed

      Imitation Training for Autism

      New Brunswick, New Jersey
      The goals of this project are to (a) incorporate empirical findings on imitation training and learning in autistic children into a comprehensive protocol for Applied Behavior Analysis practitioners designed to rapidly facilitate generalized imitation called Emergent Multi-Class Imitation Training (EMIT), and (b) collect pilot data on the efficacy of EMIT with a small sample of autistic children. EMIT will incorporate several features that are grounded in prior research including: (a) evidence-based procedures for establishing trained matching relations (a pre-requisite to generalized imitation), (b) concurrent training of different response types (e.g., motor imitation, object imitation, vocal imitation) to address restricted generalization, (c) multiple manipulative object imitation training, (d) evidence-based procedures for remediating slow acquisition, and (e) frequent tests for the emergence of generalized imitation. EMIT will be the first protocol designed for clinical use that reflects research findings on imitation learning spanning almost five decades.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:12 - 6

      Key Eligibility Criteria

      Disqualifiers:Intellectual Disability, Motor Conditions, Visual, Others

      25 Participants Needed

      Non-invasive Brain Stimulation for Autism

      New Brunswick, New Jersey
      Although many children diagnosed with autism spectrum disorder (ASD) make significant progress in learning and their cognitive skills improve with applied behavior analysis (ABA), there are a significant number of children who show an absence or a plateau in various skills. Deficits in executive functioning are likely to be involved in many of these cognitive and learning disabilities due to poor functioning of the prefrontal cortex. Currently, the use of biological methods for improving learning and cognition is largely unexplored in research and practice. The aim of this study is to use of transcranial direct current stimulation (tDCS) in combination with ABA to improve the acquisition of educational programs for students with ASD. tDCS is a low-level electrical neurostimulation and is most effective when used in combination with an active training or teaching, facilitating the neuronal circuits used for that task. tDCS has been used for various indications over a couple of decades and has been shown to be very safe and has been well-tolerated by children with ASD. The mechanism of tDCS is not clear, however animal studies show that tDCS can stimulate the flow of calcium ions through channels in the astrocytes, activating them, and facilitating their role in synapse formation and therefore learning.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:5 - 12

      Key Eligibility Criteria

      Disqualifiers:Metal Implants, Seizure Disorder, Others
      Must Not Be Taking:Antiseizure, Antipsychotics, Stimulants, Barbiturates

      24 Participants Needed

      Propranolol for Autism

      New Brunswick, New Jersey
      Severe challenging behaviors such as aggression and self-injury can cause significant morbidity and decrease the quality of life for individuals with Autism Spectrum Disorders (ASD). There are only two medications (Risperdal and Abilify) rigorously studied and FDA-approved for the treatment of irritability in individuals with ASD. These medications are not always successful and have many short and long-term side effects. Well-designed studies demonstrating efficacy and safety of alternative medication treatment choices are needed. There is preliminary evidence that high-dose propranolol can be effective in individuals with ASD who display severe aggression and have not responded to antipsychotics or mood stabilizers. Concerns regarding the safety of high dose propranolol have limited its clinical application. Well-designed clinical trials demonstrating the efficacy and safety of high dose propranolol will have significant effects on clinical practice and improve the physical and behavioral quality of life for an underserved subset of individuals with ASD. This study will pilot the safety and efficacy of high dose propranolol. The investigators will randomly assign participants to either propranolol or to placebo later crossing each participant over to the other group. As propranolol can cause changes in blood pressure and heart function, each participant will complete initial comprehensive testing to monitor cardiac safety throughout the study. The investigators will be utilizing telemedicine and computer based telemetry to minimize the burden of office visits on the individual and family.

      Trial Details

      Trial Status:Active Not Recruiting
      Age:12 - 30

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      6 Participants Needed

      Sertraline for Anxiety in Neurodevelopmental Disorders

      Montreal, Quebec
      There are currently no approved medications for the treatment of anxiety in children and youth with neurodevelopmental disorders (NDDs), both common and rare. Sertraline, a selective serotonin reuptake inhibitor, has extensive evidence to support its use in children's and youth with anxiety but not within NDDs. More research is needed to confirm whether or not sertraline could help improve anxiety in children and youth with common and rare neurodevelopmental conditions. This is a pilot study, in which we plan to estimate the effect size of reduction in anxiety of sertraline vs. placebo. across rare and common neurodevelopmental disorders, and determine the best measure(s) to be used as a primary transdiagnostic outcome measure of anxiety, as well as diagnosis specific measures in future, larger-scale clinical trials of anxiety in NDDs.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:8 - 17

      Key Eligibility Criteria

      Disqualifiers:Diabetes, HIV, Hepatitis, Others
      Must Not Be Taking:SSRIs, MAOIs, Pimozide, Others

      130 Participants Needed

      Probiotics for Autism

      Montreal, Quebec
      Children with autism spectrum disorder (ASD) present with stereotyped behaviors and often with comorbidities including gastrointestinal symptoms and sleep disturbances. These affect the quality of life of both children and parents. As of now, interventions available to manage ASD-related behaviors rely heavily on the services of professionals who are often difficult to access. What is even more striking is that there are currently no approved medications to treat the core symptoms of ASD. There is an important need for additional strategies to manage severity of ASD and to develop new treatments. Targeting the bacteria living in the intestine, named 'gut microbiota', by using probiotics is an avenue that has been proposed by other groups to improve behaviors associated with ASD and gastrointestinal symptoms. However, these studies have important limitations, pressing the need for robustly designed interventions. Previously, the PROBI-O-TISM pilot study was conducted at CHU Sainte-Justine. The investigators confirmed that the Bio-K+ probiotic beverage is acceptable and safe for autistic children and that the proposed study protocol is feasible. The study also led to promising preliminary results suggesting a beneficial effect of the probiotics on behaviors, gastrointestinal symptoms and sleep. The proposed study will answer the question: ''Does supplementing with Bio-K+ probiotics reduce the severity of autistic behaviors and comorbidities in children with a diagnosis of ASD? '' The investigators will use a solid study design, a double-blinded randomized controlled-trial with placebo, to test the efficacy of a 14-week treatment with daily Bio-K+ probiotic supplement in children aged 4 to 11 years old. The investigators will also study the impact of the supplementation on other parameters such as quality of life, gut microbiota and brain signaling. This is a unique opportunity to test a simple approach to improve behaviors and comorbidities in autistic children.

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased
      Age:4 - 11

      Key Eligibility Criteria

      Disqualifiers:Epilepsy, Cancer, Diabetes, Others
      Must Not Be Taking:Antibiotics, Probiotics

      108 Participants Needed

      BRIGHT Coaching Program for Developmental Disabilities

      Montréal, Quebec
      Children with, or at elevated risk for, brain-based developmental disabilities can experience lifelong consequences and challenges throughout their development. In particular, preschool years (3-6 years of age) can be stressful as families wait to get services and care for their child. Nationally and internationally, service delivery models during this critical period are not standardized, and differ within and across provinces and across patient conditions, leading to long wait times, service gaps and duplications. This study has two main hypotheses: 1. A standardized approach to "coaching" (i.e. coach + online education tools + peer support network) is feasible in the real-life context, and acceptable to caregivers and can be delivered across multiple sites in urban/suburban/rural settings. 2. A standardized approach to "coaching" enhances parental health (parents' empowerment and sense of competence, quality of life, and minimizes parenting stress), family health care experience (care coordination experience and process of care) at similar health care cost (economic analysis), when compared to usual and locally available care.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Age:18 - 54

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      306 Participants Needed

      Community Engagement for Autism

      Philadelphia, Pennsylvania
      The Centering Autistic Perspectives for Behavioral Interventions Discussions (CAPBID) PCORI Science of Engagement Award will examine different community engagement approaches for bringing together autistic people, Applied Behavioral Analysis (ABA) providers, and other members of the autism community to advance a shared equitable dialogue around research priorities for ABA-related research. One of these approaches will be based on existing transformative and restorative justice methods and frameworks. This project also utilizes a community-driven participatory research approach that will center autistic leadership in all aspects of the project. The investigators hope that this research will pave the way for creating spaces where autistic people are heard in their experiences and can collaborate effectively with open-minded ABA providers about how to advance the next generation of care and research in the field. More broadly, the investigators aim to create engagement approaches that may be used to have conversations around critical and difficult issues faced by the autistic and autism communities, as well as other marginalized communities.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Under 18, Non-English Speakers

      200 Participants Needed

      TUNE In for Autism

      Philadelphia, Pennsylvania
      The purpose of this study is to test a novel, cognitive behavioral treatment strategy to improve social functioning in adults with autism spectrum disorder. The treatment, named TUNE In (Training to Understand and Navigate Emotions and Interactions), includes components to address the many behavioral domains involved in social functioning, including social motivation, social anxiety, social cognition, social skills, and generalization of the skills to community settings. The Investigators will test the efficacy of TUNE In to improve social functioning in adults with autism spectrum disorder (ASD), using a randomized controlled trial using the SRS-2 as the primary outcome measure.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Severe Behaviors, Major Mood Episode, Others

      40 Participants Needed

      Remaking Recess for Autism

      Philadelphia, Pennsylvania
      This trial tests Remaking Recess, a program that helps children with autism or developmental disorders engage socially during school recess. It targets children aged 5-12 and involves training school staff to support these children in social interactions through structured play activities. Remaking Recess is designed to improve peer engagement for children with autism spectrum disorder (ASD) during recess.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:5 - 12

      Key Eligibility Criteria

      Disqualifiers:No ASD/NDD Diagnosis, Not Under-resourced, Others

      264 Participants Needed

      SDARI Program for Autism

      Philadelphia, Pennsylvania
      This is a clinical trial that will test whether a group program called SDARI (Socio-dramatic Affective Relational Intervention) can help autistic young adults between the ages of 18 and 30 feel more connected to others and improve their social relationships. The study will try to answer: Can SDARI be used successfully with autistic adults? Does SDARI help people feel more connected, supported, and mentally well? There are two groups in the study. One group will participate in the SDARI program, and the other group will do different structured activities that don't focus on social connection. Researchers will compare the two groups to see if SDARI leads to better outcomes. Participants will: Complete screening to confirm eligibility (including autism traits and IQ) Attend weekly in-person group sessions for 10 weeks Take part in games and activities designed to support connection and collaboration Complete surveys and interviews before, during, and after the program Have the option to choose someone close to them (like a friend or family member) to fill out surveys about their experiences
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 30

      Key Eligibility Criteria

      Disqualifiers:Severe Medical, Psychiatric Condition, Others

      54 Participants Needed

      RUBI Program for Autism Spectrum Disorder

      Philadelphia, Pennsylvania
      The goal of this clinical trial is to evaluate if a redesigned version of the RUBI parenting intervention can reduce challenging behaviors and improve adaptive skills in autistic adults with co-occurring challenging behaviors. The main questions it aims to answer are: * Is the redesigned RUBI intervention feasible and acceptable for autistic adults and their families? * Does the redesigned RUBI intervention reduce challenging behaviors and enhance the quality of life for autistic adults? * Researchers will compare the redesigned RUBI intervention to an active control group, Introduction to the Science and Lived Experience of Autism (ISLEA), to see if RUBI is more effective in improving outcomes for autistic adults and their families. Participants will: * Attend sessions where they receive either the RUBI intervention or the ISLEA program. * Engage in activities designed to promote communication, co-regulation, and autonomy in the context of supporting autistic adults. * Complete assessments at the start, throughout, and at the end of the 20-week trial to evaluate outcomes such as challenging behaviors, adaptive skills, and quality of life.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      80 Participants Needed

      Motivation Treatments for Autism Spectrum Disorder

      Philadelphia, Pennsylvania
      The goal of this clinical trial is to enhance motivation to complete daily living skills among 16 to 25-year-old autistic teens and young adults. Here are the main questions the trial aims to answer: Can this trial improve motivation to complete daily living skills for skills that people know how to do but struggle to do them consistently? Can this trial improve completion of the daily living skill that the participant identifies they want to do more often? Do people report feeling more empowered to complete the daily living skill they want to do more often? Are there any characteristics of a person that make them more or less likely to benefit from the treatment? Researchers will compare treatments that target different types of motivation: * One treatment focuses on internal motivation and explores what is important to someone and then connect that value back to their daily living skill goal. * A second treatment focuses on external motivation and will explore a person finding outside sources of motivation, like rewards. * A third treatment will use a combination of both methods. Autistic teens and young adults enrolled in this study will also be asked to choose someone in their life to be involved in the study with them. This person is called an "Important Person" (IP) and can be anyone close to them, like a family member, friend, roommate, partner, etc. The IP will be expected to support the teen/young adult throughout this treatment. Participants and their IPs will: * Complete five 'talk' therapy sessions that will last 60 to 90 minutes. The IPs will join the last 15 minutes of each session) * Be assigned to one of the three motivation treatments * Fill out questionnaires before the first session, after sessions 2 through 5, and 2 weeks after therapy ends
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:16 - 25

      Key Eligibility Criteria

      Disqualifiers:Intellectual Disability, Suicide Risk, Psychiatric Disorder, Others
      Must Not Be Taking:Psychotropic Medications

      180 Participants Needed

      CAPS Program for Autism

      Philadelphia, Pennsylvania
      The number of autistic adults reached 5.4 million in the United States in 2017 and is projected to continue to rise, but evidence-based practices to optimize their health and well-being are limited and poor outcomes are common. This study will leverage existing infrastructure to finalize the development of a novel support service provided by peers with lived experience, incorporating input from autistic peer specialists, autism researchers, peer support researchers, and experts in peer support training. Investigators will then conduct a pilot randomized controlled trial to examine the effectiveness of the service while also examining the feasibility, acceptability, and implementation procedures in preparation for future large-scale testing and dissemination.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:18 - 30

      Key Eligibility Criteria

      Disqualifiers:Unable To Provide Informed Consent

      40 Participants Needed

      Suicide Prevention Interventions for Autism

      Philadelphia, Pennsylvania
      This trial is testing two methods to prevent suicide in autistic youth aged 12-24. One method involves creating a personalized safety plan, while the other adds ongoing support through periodic check-ins. The safety plan helps individuals recognize warning signs and use coping strategies, and the check-ins provide continuous support.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:12 - 99

      Key Eligibility Criteria

      Disqualifiers:Acute Psychosis, Intoxication, Mania, Others

      1665 Participants Needed

      Cognitive Behavioral Therapy for Caregiver Insomnia

      Philadelphia, Pennsylvania
      This trial tests two types of sleep therapy for caregivers of children with Autism Spectrum Disorder (ASD) who have trouble sleeping. One therapy is done at home, and the other is done online. The goal is to see which method helps improve sleep for both the caregivers and their children.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:3 - 100

      Key Eligibility Criteria

      Disqualifiers:Epilepsy, Diabetes, Down Syndrome, Others

      80 Participants Needed

      Digital Health App for Autism

      Philadelphia, Pennsylvania
      School-based behavioral approaches to managing challenging behaviors in children with ASD are limited by three key factors: 1) children with ASD often have difficulties communicating their emotions; 2) it is challenging to implement evidence-based, personalized strategies for individual children, and; 3) it is difficult for teachers to track which strategies are successful for individual children. The investigators' personalized mobile-health emotion regulation application (m-health app) will pair heart rate tracking with digital tools to help reduce challenging behavior by supporting stress detection, reminding teachers of specific behavioral strategies and helping teachers to track progress.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:3 - 13

      Key Eligibility Criteria

      Disqualifiers:No Challenging Behaviors

      20 Participants Needed

      Mind the Gap Intervention for Autism

      Philadelphia, Pennsylvania
      The AIRB research team will compare the use and effectiveness of each intervention (Mind the Gap, Remaking Recess and Self Determination Learning Model of Instruction) with and without the addition of an implementation strategy, UNITED. In all groups, the research team will train community practitioners using remote delivery of professional development modules specific to the intervention, and active coaching for up to 12 sessions as dictated by the intervention procedures during a time span of 6 months. The research team will pair UNITED with three interventions that cover the ages of early childhood, childhood, and adolescence. These include Mind the Gap (MTG), a family navigation intervention for children newly diagnosed under age 8, Remaking Recess (RR), a school-based social/peer engagement intervention for children ages 5-12, and Self-Determination Learning Model of Instruction (SDMLI), a self-advocacy intervention for adolescents (13-22 years; 22 is the upper age limit of high school for individuals with disabilities). For MTG, peer navigators (staff working in an organization that already works with parents) and parents (with children with ASD) will meet via phone or video conference for up to 12 sessions within a 6 month span (an hour each time). They will go over sessions that were created by the research group that help parents understand the system of acquiring services. The total time commitment for peer navigators is about 18 hours and for parents with children with ASD is about 8.5 hours. Identified families connected to the community organization will be matched with one peer navigator who will then guide and support the caregiver through completion of the MTG modules with active coaching of the family. Family needs and preferences will guide topic selection. Active coaching will occur via zoom, or over the phone, based on family preference and some recorded sessions will be shared with the research group for analyses. Mind the Gap will be available in English, Spanish, and Korean.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:2+

      Key Eligibility Criteria

      Disqualifiers:Children Under 2 Or Over 8, Others

      308 Participants Needed

      PEACE Toolkit for Autism

      Philadelphia, Pennsylvania
      Investigators will test the impact of the PEACE implementation toolkit and determine the level of implementation support needed to improve early intervention providers use of caregiver coaching with families of young children with autism who receive early intervention services. The study will also assess caregiver and child outcomes for families receiving caregiver coaching and the cost effectiveness of the PEACE implementation toolkit. The investigators will enroll 200 early intervention providers, and 400 parent-child dyads.

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Unphased
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Non-English/Spanish Speakers

      600 Participants Needed

      Enhanced Milieu Teaching for Language Disorders

      Philadelphia, Pennsylvania
      Children with poor early language skills are at risk for academic, social, vocational, and health difficulties across the lifespan. Parent training-as part of early language intervention-is a cost-effective option to address this public health issue, but these interventions demonstrate large individual differences in outcomes and barriers to scalability. The purpose of this research is to examine parent-level predictors of early language interaction quality and modifiability during training, which will help increase intervention effectiveness.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:30+

      Key Eligibility Criteria

      Disqualifiers:Hearing Loss, Down Syndrome, Others

      300 Participants Needed

      Why Other Patients Applied

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31
      Match to a Autism Trial

      Cognitive Behavioral Therapy for Anxiety in Autism

      Philadelphia, Pennsylvania
      Anxiety is very common in autistic youth. Recently, an intervention has been created by the investigators to target these symptoms in autistic youth in a community setting. The purpose of this study is to determine the feasibility of implementing this treatment in community care centers.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:7 - 17

      Key Eligibility Criteria

      Disqualifiers:Psychotic Disorder, Severe Suicidal Ideation, Concurrent Psychotherapy, Others

      60 Participants Needed

      Measurement Feedback App for Autism Spectrum Disorder

      Philadelphia, Pennsylvania
      The goal of this clinical trial is to test whether a smartphone-based data collection and feedback application ("Footsteps") improves the quality of behavioral data collected by one-to-one aides and leads to better youth mental health outcomes in school-aged youth (ages 4-17) who receive one-to-one support in schools. The main questions it aims to answer are: 1. Does the Footsteps app improve aides' data collection quality (i.e., consistency, timeliness, and completeness)? 2. Does Footsteps use lead to improved youth behavioral health outcomes (e.g., SDQ, YTP, GAS scores)? 3. Does Footsteps improve communication and supervision processes between aides and clinical supervisors? Researchers will compare aides using Footsteps to those using a "data collection only" control app to see if Footsteps leads to higher quality data collection, enhanced supervisory communication, and better youth outcomes. Participants will: * Use either Footsteps or a control app to record de-identified data on one client's behaviors and skills over 12 weeks * Complete biweekly online surveys about data collection experiences, youth progress, and aide-supervisor communication * Participate in a virtual intake and post-trial meeting * (For a subset) Participate in a 30-45 minute qualitative interview about their experience using the app
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Pilot Trial Participants

      200 Participants Needed

      Social and Communication Intervention for Autism

      Media, Pennsylvania
      This trial tests a school program designed to help young children with autism improve their language and social skills. It focuses on preschool-aged children who need extra help in these areas. Teachers are trained to use special techniques and get feedback to improve their methods.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:3 - 6

      Key Eligibility Criteria

      Disqualifiers:Head Injury, Serious Physical Injury, Others

      700 Participants Needed

      Transcranial Magnetic Stimulation for Autism

      Newark, Delaware
      There is no consensus regarding the neurological substrate underpinning ASD. The investigators describe the novel concept of "social reciprocity network" and hypothesize that aberrant connectivity/oscillatory patterns affecting this network contribute to the core deficits in ASD. The overarching goal of this trial is to explore abnormalities involving the neuronal connectivity and oscillatory patterns within the social reciprocity network and to elucidate the role of modulating this network via rTMS in improving the above measures and social cognition in ASD. Quantitative electroencephalography (QEEG) coherence and spectral power analysis are reliable measures of neuronal connectivity and dynamics. The investigators aim to study the QEEG coherence/spectral power analysis to explore the neuronal dynamics affecting the social reciprocity network in ASD.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:13 - 18

      Key Eligibility Criteria

      Disqualifiers:Significant Anxiety, Seizures, Metallic Implants, Others

      12 Participants Needed

      Game-Based Mobile App for Autism

      Newark, Delaware
      The clinical study aims to develop and test a gamified mobile health app called PuzzleWalk (PW) to promote physical activity (PA) and reduce sedentary behavior (SB) in autistic adults, including those with mild intellectual disabilities (ID). The study addresses the need for tailored interventions in this population, who are at higher risk for lifestyle-related chronic health conditions due to lower PA and higher SB. The upgraded version of PuzzleWalk integrates behavior change techniques and gamification strategies, such as translating step counts into puzzle game playtime, to encourage regular PA and reduce SB. The study will evaluate the app's effectiveness on preventive health behavior changes in real-world settings. The ultimate goal is to create an effective, sustainable, and scientifically validated mobile health tool to improve the health and well-being of autistic adults.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:Moderate-to-profound ID, Orthopedic Conditions

      75 Participants Needed

      DTT + JASPER for Autism

      Rochester, New York
      This trial aims to improve language skills in preschool children with autism using a structured teaching and social interaction-based learning program. The program is adjusted based on each child's progress. The goal is to help these children develop better communication skills and avoid being minimally verbal by age 6.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:36 - 59

      Key Eligibility Criteria

      Disqualifiers:Sensory Impairments, Genetic Syndromes, Others

      140 Participants Needed

      Suramin for Autism

      Baltimore, Maryland
      Suramin has been found to correct the symptoms, metabolism, and brain synaptic abnormalities in two classical genetic and environmental mouse models of autism. A preliminary clinical trial (SAT-1) examined the safety and activity of a single low-dose of suramin in children with ASD and concluded suramin showed promise as a novel approach to treatment of ASD. The current study, STAT-2A, will be a randomized, double-blind, crossover, 30-week study to evaluate the preliminary proof of concept, safety, and PK of suramin sodium (KZ101) with repeat dosing by IV infusion in males 5-14 years of age who have been diagnosed with ASD. The study will be conducted at approximately 3 sites contributing approximately 15 subjects per site. Total enrollment of approximately 45 subjects is planned to achieve approximately 36 participants completing the study.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:5 - 14
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Syndromic ASD, Severe Comorbidities, Organ Dysfunction, Others
      Must Not Be Taking:Sulfonamides, Chlorpromazine, Anticoagulants

      45 Participants Needed

      CBD for Autism

      Baltimore, Maryland
      This trial is testing if cannabidiol (CBD) can help with anxiety, mood issues, sleep problems, and agitation in adults with autism spectrum disorder (ASD). Participants will take CBD pills for a period of time. The study aims to see if CBD is effective and safe for these psychiatric problems. Cannabidiol (CBD) has shown promise in treating psychotic symptoms and anxiety, but there is not enough high-quality evidence for its clinical use in psychiatric disorders.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Substance Use Disorder, Pregnancy, Others
      Must Not Be Taking:Clobazam

      40 Participants Needed

      Reinforcement Strategies for Intellectual Disabilities

      Baltimore, Maryland
      This study is designed to better understand how certain features of reinforcement affect learning and motivation in individuals with intellectual and developmental disabilities (IDD). Participants will take part in a series of structured teaching sessions that involve simple tasks and reward-based feedback. By changing the timing and amount of rewards, we aim to learn how these factors influence the ability to acquire and maintain new skills. This information may help improve behavioral interventions for individuals with IDD in the future. The study does not involve medications or procedures intended to change participants' health status.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:6 - 17

      Key Eligibility Criteria

      Disqualifiers:Severe Sensory/motor Impairments, Others

      30 Participants Needed

      Cognitive Behavioral Therapy + Psychoeducation for Anxiety in Children With Autism

      Baltimore, Maryland
      Anxiety is prevalent in young children, under 7 years of age, with autism. Yet, few studies have examined anxiety interventions for this age range, and only one anxiety treatment study has included young children with cognitive and language delays. Anxiety treatment models utilizing cognitive-behavioral therapy (CBT), adapted for children with autism, are empirically supported in school-age autistic children. Further, preliminary evidence suggests CBT approaches may reduce intolerance of uncertainty (IU), a mechanistic construct that may contribute to the maintenance of anxiety in autistic children. This study seeks to address the existing gap in anxiety treatment by examining the feasibility and preliminary efficacy of a novel, telehealth CBT intervention, DINO Strategies for Anxiety and intolerance of Uncertainty Reduction (DINOSAUR), which targets both anxiety and IU in young autistic children.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:4 - 6

      Key Eligibility Criteria

      Disqualifiers:Non-English, Foster Care, Severe Behavior, Others

      70 Participants Needed

      12345

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Autism clinical trials in Boston, MA pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Autism clinical trials in Boston, MA work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Autism trials in Boston, MA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Boston, MA for Autism is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Boston, MA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Autism medical study in Boston, MA?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Autism clinical trials in Boston, MA?

      Most recently, we added Prednisone for Autism, Community Engagement for Autism and SDARI Program for Autism to the Power online platform.

      Is there still a spectrum for autism?

      Yes—medical guidelines still call it Autism Spectrum Disorder, but experts no longer picture that spectrum as a single line from “mild” to “severe.” Instead, it’s more like a sound-mixing board with many sliders: social communication, repetitive behaviors, sensory sensitivity, thinking style, and support needs can each sit at different points, creating a unique profile for every autistic person. Clinicians note these differences by assigning support levels (1-3) in each domain so interventions can be tailored rather than ranked.

      What is the biggest symptom of autism?

      There isn’t one “biggest” symptom of autism; doctors look for a pattern that includes BOTH social-communication differences (like trouble reading body language or carrying on back-and-forth conversation) and restricted, repetitive behaviours or intense interests/sensory sensitivities (such as needing strict routines or reacting strongly to noises). Which of these stands out most varies from person to person, so if you notice a persistent mix of them, the next step is to talk with your GP or a psychologist for a formal autism assessment and tailored support.

      Can maternal stress cause autism?

      Normal day-to-day worries during pregnancy have not been proven to cause autism. Large studies show that only very severe or long-lasting stress (such as the death of a close relative or a natural disaster) is linked to a small rise in risk—about 2 % to roughly 3 %—and even that link may partly reflect other genetic or environmental factors. Taking steps to manage high stress is good for overall maternal and baby health, but parents should not blame themselves or everyday stressors if a child is later diagnosed with autism.

      What is the life expectancy of someone with autism?

      Large registry studies (e.g., Sweden 2016, Denmark 2022) find that autistic people, on average, die 15–20 years earlier than non-autistic peers, with a median age of death around the mid-50s; the figure is lower (≈ 40s) when someone also has intellectual disability or uncontrolled epilepsy and higher (late 50s or beyond) when those conditions are absent. The gap is driven less by autism itself than by treatable or preventable issues—seizures, heart disease, accidents and suicide—so good medical follow-up, mental-health support and safety planning can help many autistic individuals live into typical older age.

      What is the best treatment for autism in the world?

      There is no one “best” treatment for every person with autism; the strongest evidence shows that progress comes from an individualized program that blends proven developmental-behavioral therapies (such as Applied Behavior Analysis or other naturalistic approaches) with speech-language and occupational therapy, parent coaching, and tailored educational supports. A multidisciplinary team adjusts this mix over time—and may add medication for anxiety, ADHD, or sleep problems—so the plan fits the person’s specific strengths, challenges, and goals, which is what international guidelines recommend for the best results.

      Is autism overdiagnosed?

      Rates of autism have risen sharply (e.g., from about 1 in 150 U.S. children in 2000 to 1 in 36 today), but most of that jump comes from broader definitions, better screening, and shifting other labels to “autism,” not from a sudden epidemic. Studies suggest roughly 1 in 10 people once given the label later lose it—evidence of some over-diagnosis—yet girls, adults, and many minority children are still frequently missed, so the real problem is uneven diagnosis rather than simply “too much” or “too little.” A careful, multidisciplinary assessment that also checks for ADHD, language disorders, anxiety, and other look-alike conditions is the best way to get an accurate answer for any individual.

      Who carries the autism gene?

      There is no single “autism gene.” Autism risk comes from a mix of many common genetic variants, rare mutations, and sometimes new (de-novo) changes that neither parent had; these can be inherited from either mother or father, while factors like higher paternal age and the female-protective effect can influence how that risk shows up. In short, either parent—or neither, if the change is new—can pass along genetic risk, so talking with a genetic counselor is the best way to understand a specific family’s situation.

      Which state has the highest rate of autism?

      In the latest CDC ADDM study, the surveillance area in California recorded the highest autism rate: roughly 4.5 % of 8-year-olds (about 45 children per 1,000). However, ADDM covers only parts of 11 states and other tracking systems use different methods, so rankings can change if you look at school records, insurance data, or adult estimates—meaning the numbers are useful for spotting trends, not declaring a single “most-autistic” state.

      Has anyone ever overcome autism?

      Autism is a lifelong neuro-developmental difference, so people don’t “overcome” it in the sense of being cured; instead, most continue to be autistic throughout life. With early, individualized supports and ongoing accommodations, many children and adults make major gains—some even lose the formal diagnosis—yet they often keep certain autistic traits and still benefit from understanding and acceptance. The practical aim is therefore not to erase autism but to build skills, reduce distress, and create environments where each autistic person can thrive.

      What was autism called in the 1980s?

      In the early-1980s diagnostic manual (DSM-III, 1980) autism was officially listed as “Infantile Autism,” and in the 1987 revision (DSM-III-R) the name was changed to “Autistic Disorder” under the larger category of “Pervasive Developmental Disorders.” Outside the U.S., doctors using the World Health Organization’s ICD-9 still called it “Childhood Autism.” In everyday practice, people might also have heard “Kanner’s autism” or “childhood psychosis,” but the two formal labels you would have seen on a medical chart during that decade were “Infantile Autism” at the start of the 1980s and “Autistic Disorder” by the end.

      Popular Searches

      By Condition

      Depression Clinical Trials in Massachusetts

      Anxiety Clinical Trials in Massachusetts

      Schizophrenia Clinical Trials in Massachusetts

      ADHD Clinical Trials in Massachusetts

      Bipolar Disorder Clinical Trials in Massachusetts

      Multiple Sclerosis Clinical Trials in Massachusetts

      Autism Clinical Trials in Massachusetts

      Treatment Resistant Depression Clinical Trials in Massachusetts

      Borderline Personality Disorder Clinical Trials in Massachusetts

      Social Anxiety Disorder Clinical Trials in Massachusetts

      Parkinson's Disease Clinical Trials in Massachusetts

      Alzheimer's Disease Clinical Trials in Massachusetts

      By Location

      Clinical Trials near Boston, MA

      Clinical Trials near Worcester, MA

      Clinical Trials near Springfield, MA

      Clinical Trials near Burlington, MA

      Clinical Trials near Fall River, MA

      Clinical Trials near Cambridge, MA

      Clinical Trials near North Dartmouth, MA

      Clinical Trials near Newton, MA

      Clinical Trials near Waltham, MA

      Clinical Trials near Watertown, MA

      Clinical Trials near Belmont, MA

      Clinical Trials near Brockton, MA

      Other People Viewed

      By Subject

      81 Autism Trials near Phoenix, AZ

      38 Autism Trials near New York, NY

      30 Autism Trials near Albuquerque, NM

      24 Autism Trials near Anaheim, CA

      20 Autism Trials near Ventura, CA

      25 Autism Trials near Philadelphia, PA

      23 Autism Trials near Los Angeles, CA

      12 Autism Trials near Austin, TX

      Top Attention-Deficit/Hyperactivity Disorder (ADHD) Clinical Trials near Boston, MA

      Top Obsessive Compulsive Disorder Ocd Clinical Trials near Boston, MA

      Top Lung Cancer Clinical Trials near Boston, MA

      Top Autism Clinical Trials

      By Trial

      Simulation-Based Training for Autism

      Sulforaphane for Autism

      Folinic Acid for Language Impairment in Autism Spectrum Disorder

      Vasopressin Nasal Spray for Autism

      Sleep Intervention for Autism Spectrum Disorder

      FMT for Autism

      Retrieval-based Word Learning for Developmental Language Disorder

      Early Literacy Program for Preterm Infants

      Brain Stimulation for Dyslexia

      Text Messaging for Parenting After Child's Psychiatric Emergency

      Naps for Infant Memory Development

      Pseudoword Learning for Aphasia

      Related Searches

      Top Autism Clinical Trials near Anaheim, CA

      Top Autism Clinical Trials near Long Beach, CA

      Top Autism Clinical Trials near New York, NY

      TUB-040 for Ovarian and Lung Cancers

      mRNA Vaccine for Flu

      Zongertinib for Liver Disease

      Regenerative Cell Therapy for Rotator Cuff Tears

      Probiotic Transmission Between Infants

      Nociscan for Discogenic Low Back Pain

      Pain Self-Management for Postoperative Pain

      Top Glaucoma Clinical Trials near Miami, FL

      Distress Screening Program for Cancer